CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 10 target
Drug / intervention
Nivolumab +1 moredrug
Likely dose
Not stated in record
Key inclusion· 6
  • ✓Age 18 years or older
  • ✓Diagnosed with stage III pancreatic cancer
  • ✓Measurable tumor
  • ✓Glomerular Filtration Rate greater than 60 mL/min/1.73 m²
Key exclusion· 5
  • ✕Currently participating in another clinical trial for cancer treatment
  • ✕Pregnant or currently breastfeeding
  • ✕Cardiac pacemaker or ICD that cannot be deactivated during procedure
  • ✕Non-removable metal implants within 1 cm of target lesion

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03080974
NCT03080974Phase 2RecruitingOn TrackUpdated 8mo ago
Long Recruiting
CompareCT.gov

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

University of Louisville·interventional·Posted Mar 15, 2017·Updated Oct 29, 2025

In Brief

A Phase 2 clinical trial evaluating Nivolumab and Irreversible Electroporation for Pancreatic Adenocarcinoma. Currently recruiting, targeting 10 participants across 1 site.

Detailed Summary

Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Adenocarcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2Recruiting
2017201820192020202120222023202420252026202720282029
First PostedMar 15, 2017
Enrollment StartAug 14, 2017
Primary CompletionJun 1, 2028
Study CompletionApr 1, 2029
TodayJul 2, 2026
Enrollment to primary: 10.8 yearsPosted 9.3 years agoPrimary completion in 1.9 years

Interventions

Nivolumabdrug

Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.

Irreversible Electroporationprocedure

Non-thermal ablation of tumor